Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies.

Autor: Batten LM; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Bhattacharya IS; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Moretti L; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Haviland JS; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Emson MA; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Miller SE; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Jefford M; 2National Cancer Research Institute, Angel Building, 407, St John Street, Clerkenwell, London, EC1V 4AD UK., MacKenzie M; Independent Cancer Patients Voice, 17 Woodbridge St, Clerkenwell, London, EC1R 0LL UK., Wilcox M; Independent Cancer Patients Voice, 17 Woodbridge St, Clerkenwell, London, EC1R 0LL UK., Hyslop M; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Todd R; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Snowdon CF; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK., Bliss JM; 1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton, London, SM2 5NG UK.
Jazyk: angličtina
Zdroj: Research involvement and engagement [Res Involv Engagem] 2018 Jul 16; Vol. 4, pp. 22. Date of Electronic Publication: 2018 Jul 16 (Print Publication: 2018).
DOI: 10.1186/s40900-018-0108-0
Abstrakt: Plain English Summary: Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast cancer clinical trials where multiple biopsies are required. ICR-CTSU recognises that patient advocates (patients who have previously had, or cared for someone with, cancer) are key members of the trial design group and should be involved in the clinical trial throughout its lifespan. Patient advocates can provide reassurance regarding the acceptability of trial designs involving multiple biopsies from a patient perspective. This paper summarises patient advocate involvement in ICR-CTSU breast cancer trials activity and how this has benefited our research.
Abstract: The importance of collecting tissue samples in breast cancer has become increasingly recognised, as the diversity of the disease has become better known. It has been documented in recent research that tumours may change in response to treatment prior to surgery (the neoadjuvant treatment setting). The collection of sequential biopsies over time can identify changes within tumours and potentially predict how the tumour may respond to certain treatments. However, the acceptability of multiple biopsies amongst patients, clinicians and other research staff in hospitals is variable and recruitment into clinical trials requiring multiple biopsies may be challenging.The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) is responsible for a portfolio of breast cancer trials where multiple biopsies are key to the trial design. Patient advocate involvement has been essential in helping us to design and deliver complex and innovative cancer trials which require multiple invasive tissue biopsies, often without any direct benefit to the trial participants. The views expressed by patient advocates involved in ICR-CTSU trials supports the published evidence that patients are willing to donate additional tissue for research and that clinicians' concerns about approaching patients for trials involving multiple biopsies are often unfounded.Patient advocate involvement in ICR-CTSU trials activity takes various forms, from membership on protocol development groups and trial management groups, attendance at focus groups and forums, and presentations at trial development and launch meetings. This involvement has provided reassurance to research teams within the NHS and research ethics committees of the importance and acceptability of our trials from a patient perspective. Patient advocate involvement throughout the lifetime of our trials ensures that the patient remains central to our research considerations.
Competing Interests: All clinical trials mentioned by name in this paper had full ethical review and approval, all patients that took part with the studies consented to do so. Further details: IMPACT was approved first by a national multicenter research ethical committee and subsequently by individual local research ethics committees; POETIC – South East Research Ethics Committee, 08/H1102/37; PALLET – London Fulham Research Ethics Committee, 14/LO/1291.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Databáze: MEDLINE
Externí odkaz: